Clinical Trial Update: Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update for CHT101, a universal anti-CD70 CAR-T cell therapy for relapsed/refractory systemic lupus erythematosus; the study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CHT101 (CHT101)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Systemic Lupus Erythematosus (SLE) | EARLY_Phase 1 | Status: RECRUITING